← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,135	+22	+2%	$52.7B
2	2 Danaher DHR $158B	1,127	+22	+2%	$45.7B
3	3 Novartis NVS $279B	910	+5	+0.6%	$19.9B
4	4 Regeneron Pharmaceuticals REGN $80.1B	579	+3	+0.5%	$27.9B
5	5 Agilent Technologies A $49.1B	552	-1	-0.2%	$14.7B
6	6 Illumina ILMN $41B	530	+1	+0.2%	$23.6B
7	7 Revvity RVTY $17B	310	-16	-5%	$5.88B
8	8 Charles River Laboratories CRL $14.4B	300	+3	+1%	$4.2B
9	9 Ionis Pharmaceuticals IONS $7.1B	271	-38	-12%	$4.46B
10	10 Myriad Genetics MYGN $397M	233	+10	+4%	$1.61B
11	11 DELISTED bluebird bio BLUE	210	+11	+6%	$4.24B
12	12 DELISTED CATALENT, INC. CTLT	209	+3	+1%	$3.64B
13	13 Bruker BRKR $8.47B	202	-10	-5%	$2.52B
14	14 Alnylam Pharmaceuticals ALNY $30B	199	-12	-6%	$4.22B
15	15 Azenta AZTA $1.63B	196	+15	+8%	$1.45B
16	16 Qiagen QGEN $9.41B	183	+165	+917%	$4.12B
17	17 Sarepta Therapeutics SRPT $1.78B	180	+2	+1%	$1.21B
18	18 Ultragenyx Pharmaceutical RARE $1.47B	165	-10	-6%	$2.76B
19	19 Precigen PGEN $2.64B	154	-17	-10%	$1.99B
20	20 DELISTED SANGAMO THERAPEUTICS INC SGMO	118	-8	-6%	$241M
21	21 PTC Therapeutics PTCT $4.98B	115	-8	-7%	$310M
22	22 Pacific Biosciences PACB $619M	106	-9	-8%	$406M
23	ISEE 23 DELISTED IVERIC bio, Inc. Common Stock ISEE	100	-37	-27%	$97.4M
24	24 Editas Medicine EDIT $349M	99	+15	+18%	$614M
25	SIOX 25 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	97	-4	-4%	$1.63B